Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Ulcerative Colitis
A study for patients with moderate to severe ulcerative colitis using study drug LY3074828
Sponsor: Eli Lilly and Company
Enrolling: Male and Female Patients
IRB Number: AAAQ6718
U.S. Govt. ID: NCT02589665
Contact: Simon Lichtiger: 212-305-1021 / sl3687@cumc.columbia.edu
Additional Study Information: This study is being done to see how safe and effective this investigational drug is and how well it is tolerated in subjects with ulcerative colitis. This study will study the safety of LY3074828 and any side effects one might have when they take it and how much LY3074828 should be given to subjects.
This study is closed
Investigator
Simon Lichtiger, MD
Do You Qualify?
Have you been diagnosed with ulcerative colitis? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Simon Lichtiger
sl3687@cumc.columbia.edu
212-305-1021
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE